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Abstract 
Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecological 
malignancies due to its non-specific symptoms, poor screening methods, lack of reliable 
biomarkers, and our limited knowledge of the cellular and molecular mechanisms underlying the 
disease. As in all cancers, uncontrolled cell growth resulting from a deregulated cell cycle lies at 
the core of the cellular aspects of EOC. Normal cell cycle regulation is maintained through 
temporal expression of canonical cyclin molecules, which then direct progression through the 
cycle by their direct binding to and activating cyclin-dependent kinases (CDKs). Cyclin G1, G2, 
and I, constitute a group of unconventional cyclins whose expression results in cell cycle arrest. 
Cyclin G2 expression has been shown to negatively regulate cell cycle and its levels are lowered 
in various types of cancer including ovarian, breast, oral, gastric, and kidney. Our lab has 
previously reported that cyclin G2 is an unstable protein, which can be degraded through the 
ubiquitin proteasome pathway. The aim of this study was to further examine how the degradation 
of cyclin G2 is regulated. Through a series of in vitro assays, we showed that cyclin G2 is a target 
of calpain’s proteolytic activity in a number of human ovarian cancer cells. Furthermore, through 
the use of inhibitors of various protein kinases we found that inhibition of epidermal growth factors 
receptor (EGFR) in those cells led to protection of cyclin G2 from degradation. Finally, we 
demonstrated that stimulation of cells with epidermal growth factor (EGF) also resulted in the 
degradation of cyclin G2. Considered together, these findings suggest that activation of EGFR and 
calpain promote cyclin G2 degradation.   
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Chapter 1: Introduction 
1.1: The Lifecycle of Eukaryotic Cells 
1.1.1: Overview of Regulatory Networks of Cellular Life 
Appropriate and steady regulation is the key to maintain the complexity and organization 
of any system that dares to go against the grain of the universal increase of entropy. The eukaryotic 
cells of the human body, each containing about 109 interacting protein molecules at any given 
time1, are a perfect embodiment of regulated complexity, which is absolutely needed for the normal 
functioning of these cells. Controlled growth and proliferation at cellular level results in normal 
development and functioning of the body. On the other hand, uncontrolled growth of cells can lead 
to many diseases, including cancer2. At the molecular level, cell growth is induced by the activation 
of cyclin-dependent kinases (CDKs), which follows their binding to their positive regulators, 
cyclins3,4. The proliferation of all eukaryotic cells is governed by the cell cycle, where temporally 
controlled biochemical events promote or halt progression through it, depending on the 
intracellular as well as extracellular conditions5. Upon completion of mitosis and cytokinesis, the 
two daughter cells can be viewed as entering a new cycle, where the environment as well as the 
biological clues will decide their fate. 
 
1.1.2: Cyclins and CDKs 
Cyclins are a class of closely related proteins6 that contain a conserved stretch of ~110 
amino acids known as the cyclin box7. The grouping of cyclins is based on their structural 
similarities as well as their temporal expression during the cell cycle8,9. The cyclin box facilitates 
the formation of CDK-cyclin complexes10 and this binding switches on the serine/threonine kinase 
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activity of CDKs, which then promotes cell cycle progression through phosphorylation of their 
substrates3,11. Even though cyclins and CDKs are the canonical drivers of the cell cycle, it is 
striking that of the 13 CDK and 25 cyclin genes identified in the human genome so far, only a 
handful are directly and exclusively involved in cell cycle regulatory pathways2. For instance, in 
addition to cell cycle regulation in different cell types,  CDK7-cyclin H as well as CDK8, CDK9, 
CDK10, and CDK11 also regulate transcription through phosphorylating different subunits of 
RNA polymerase II12-14. While intracellular levels of CDKs remain constant throughout the cell 
cycle, the expression and amount of most cyclins oscillate with the cell cycle15, and their levels 
are regulated by rapid degradation via ubiquitin-proteasome pathway (UPP)16,17 . Cyclins destined 
for destruction are ubiquitinated on their particular lysine residues by specific E3 ligases, which 
marks them for degradation in the proteasome machinery. This degradation process and rapid 
turnover is dependent on the presence of a destruction box motif in the case of cyclins A and B, or 
a PEST sequence when it comes to degradation of cyclins D and E18,19.  
 
1.1.3: Cell Cycle 
As mentioned before, after completing mitosis and cytokinesis, the two daughter cells enter 
a new cycle, starting with the G1 (Gap 1) phase of the cell cycle. During this phase, cells grow in 
size and duplicate their organelles while synthesizing the necessary proteins for DNA replication20. 
Terminally differentiated cells or actively proliferating ones that experience stress factors such as 
lack of nutrients or hypoxic conditions might exit the cell cycle and enter a quiescent state, 
commonly known as G0 phase, where cell metabolism continues, but cell cycle progression and 
subsequent cell division are blocked21. During G0, while cells continue to metabolize, they will not 
actively progress through the cell cycle. Another point of crucial decision making in G1 phase is 
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the restriction point (R), also known as the point of no return. The name stems from the fact that 
once a cell passes through this point in its cycle, it becomes committed to continue advancing 
through the cell cycle, even in the absence of growth stimulatory signals22. Consistent with the 
pattern of cancer cells’ uncontrolled growth, the R point is always bypassed in these cells to 
maintain a continuous progression through the cell cycle23. Direct association of CDK4 and CDK6 
with cyclin D1, cyclin D2, and cyclin D3 are the driving forces behind G1 phase24. To transition 
to the next phase of the cell cycle, S (synthesis), the formation of CDK2-cyclin E complex is 
required25. During this phase, cell’s nuclear genome is replicated and errors in replication are 
corrected26. Progression through S phase requires the presence of CDK2-cyclin A complex27,28. G2 
phase separates S phase from mitosis (M) and it is the most variable phase of the cell cycle among 
different species. Cell cycle is halted at the G2/M checkpoint in the presence of DNA-damaging 
stress29. Finally, CDK1-cyclin A signals entry into M and a complex of CDK1 and cyclin B 
maintains progression through mitosis30. The various combinations of CDK-cyclin complexes 
during the cell cycle are summarized in Figure 1. 
 
In contrast to cyclins, CDK inhibitors (CKIs) such as p15INK4, p16INK4, p21WAF1/CIP1, and 
p27KIP1 negatively regulate CDK activity by binding to CDK-cyclin complexes to halt the cell 
cycle when needed11,31. In addition to this internal regulatory network, cell cycle is also subject to 
extracellular stimuli, both positive and negative. Inhibitory signals can cause the cell cycle exit 
and entry into G0 as mentioned before. Growth stimulatory signals such as epidermal growth factor 
(EGF) and subsequent activation of kinase activity of its receptor (EGFR) can force cells to exit 
G0 and enter the cell cycle through upregulation of cyclin D1 for instance32. 
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Figure 1: The formation of CDK-cyclin complexes throughout the cell cycle. To initiate and 
progress through each phase, formation of specific CDK-cyclin complexes is needed. Similarly, 
in order for the cell to move on to the next phases, previously present cyclin proteins must undergo 
degradation, which then leads to deactivation of their CDK partners. The length of each phase of 
the cell cycle is highly variable amongst cells and are ultimately determined by the cell type and 
the environment in which the cells find themselves. The circular arrow at the centre shows the 
direction of the cycle. 
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1.2: Ovarian Cancer 
1.2.1: An Overview of Ovarian Cancer  
At the core, cancer is a disease of the genes; the highly celebrated and tightly regulated 
orchestra of the collective gene expression that maintains the balance between life and death of the 
cell is now left with a mad conductor with total disregard for the latter. As we saw, a rigorous 
regulatory network ensures the proper growth of healthy cells through the actions of CDK-cyclin 
complexes as well as the complimentary effects of CKIs and extracellular stimuli. The 
deregulation of this network in cancer stems from a broad range of genes that undergo mutations, 
translocations, as well as epigenetic modifications33,34, the net result of which is the loss or 
inactivity of tumour suppressor genes and unchecked activation of oncogenes, notably the ones 
that stimulate growth.  
 
Ovarian cancer (OVCA) is the collective term given to many different types of cancerous 
lesions that arise and cause disease in the ovary. More than 30 types of ovarian malignancies have 
been identified so far, making ovarian cancer a highly heterogeneous disease. These malignancies 
can be grouped into three main categories: epithelial, germ, and stromal cell carcinomas35. Of the 
three, epithelial ovarian cancer (EOC) accounts for 90% of all cases of OVCA, and it also has the 
highest mortality rate36. Poor screening methods and lack of specific EOC biomarkers often lead 
to late diagnoses of the disease, which in turn contribute to its high mortality rate. In addition, the 
symptoms caused by EOC are non-specific and often similar to those of other gastrointestinal, 
genitourinary, and gynaecological conditions37. Finally, the high resistance of EOC cells to most 
available chemotherapeutic drugs makes the situation even more dire for the patients38. Overall 
ten-year survival rate of up to 90% when treatment starts at stage I, compared to <6% when the 
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disease is being treated at stage IV highlights the absolute importance and necessity for early 
detection of EOC37. Although only 1.3% of women will develop EOC in their lifetime, the 
aforementioned factors make this disease the most lethal of all gynaecological malignancies, and 
the fifth leading cause of cancer-related deaths in women39,40.  
 
The choice of treatment for EOC patients depends on the stage at which the cancer is 
diagnosed, and the correct choice is essential, considering the poor prognosis and high relapse rate 
of EOC35. The assignment of EOC stages is based on the extent to which cancer cells have spread 
through the body and away from the ovaries. The description of EOC stages and their 
corresponding ten-year survival rates, when diagnosed and treated timely, according to latest 
guidelines of International Federation of Gynecology and Obstetrics (FIGO) are summarized in 
Table 141.  
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Table 1: Characteristics of tumours and the overall ten-year survival rates for different 
stages of EOC when detected and treated 
Stage # Tumour characteristics Ten-year survival rate 
(%) 
 
I 
 
 
Tumour limited to ovaries or fallopian tube(s) 
 
73-90 
 
II 
Tumour in one or both ovaries or fallopian tubes with 
extension into pelvic region (below pelvic brim) or 
primary peritoneal cancer 
 
45-55 
 
III 
Tumour in one or both ovaries or fallopian tubes, or 
primary peritoneal cancer spread to outside of pelvic 
region and/or metastasis to retroperitoneal lymph nodes 
 
21 
 
IV 
 
 
Distant metastasis beyond pelvis 
 
<6 
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1.2.2: Tumourigenesis and Genetic Aberrations in Ovarian Cancer 
With respect to ovarian cancer, a universal model for its pathogenesis and progression is 
not available, but attempts have been made to classify the resulting tumours based on clinical and 
molecular genetics studies133. The current model describes two main types of ovarian cancer based 
on the aforementioned classification criteria. Type I tumours consist mainly of cancerous lesions 
that find their way to the site of the ovaries and/or fallopian tubes and cause further transformation 
of cells at the site, as well as malignancies that arise from endometrioid, fallopian, and germ cells 
themselves. Most type I ovarian cancer tumours are considered low grade tumours. On the other 
hand, type II tumours are almost always the result of cancerous lesions in the fallopian tube(s) and 
histologically speaking, most of them fall in the category of high grade tumours134. 
 
As mentioned earlier, cancer is always associated with genetic aberrations, and the 
combinatorial effects of these aberrations can confer different characteristics to different tumours 
arising from the same tissue. In this regard, ovarian cancer can be calssified into two groups of 
low- and high-grade, or Type I and Type II, respectively. Low-grade serous ovarian cancer 
(LGSOC) is characterized by slow-growing tumours, and the process of tumourigenesis seems to 
follow a step-wise fashion. This class of tumour often shows less genomic instability, is less 
aggressive, and more responsive to treatment. However, due to lack of reliable biomarkers it often 
goes undetected and only shows clear symptoms at later stages. Cases of LGSOC showcase 
expression of amphiregulin (growth factor deregulation), loss of heterozygosity (LOH) on 
chromosome Xq, microsatellite instability, and mutations in PIK3CA, BRAF, and KRAS, and 
ERBB2, resulting in uncontrolled growth37. On the  other hand, tumours of high-grade serous 
ovarian cancer (HGSOC) are more aggressive and grow fast, and respond poorly to available 
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treatments. Increased genomic instability is a feature of this type of cancer, which probably 
accounts for its more aggressive nature. HGSOC genetic aberrations are often characterized by 
mutations in TP53, BRCA1 and BRCA2, and LOH on chromosomes 7q and 9p, and an abundance 
of mitotic markers associated with rapid growth42-44.  
 
An important step in tumourigenesis of EOC and most other forms of carcinoma is 
epithelial-to-mesenchymal transition (EMT), which involves epithelial cells acquiring 
mesenchymal multipotent stem cells characteristics45. A direct consequence of this transition is 
that these cells no longer require cell-cell adhesion and their ability to migrate and invade other 
tissues are greatly enhanced46. It is important to note that during development47 as well as wound 
healing in adults48, EMT is frequently employed by the body, but the process is highly regulated. 
In development, neural crest cells give rise to a slew of cell types such as endocrine, neurons and 
glial, as well as melanocytes to name a few49, and in wound healing, after the first round of EMT 
which carries the cells to the site of injury, they undergo mesenchymal-to-epithelial transition 
(MET) to then cover the wound as fresh and healthy epithelial cells. Healthy epithelial cells 
covering ovarian surface regularly undergo EMT for post-ovulatory wound healing as well50. 
However, the loss of EMT regulation can give rise to epithelial cells that can then migrate and 
invade other tissues, resulting in tumour growth46. In summary, cancer cells that have undergone 
EMT rely less on cell-cell adhesion and acquire more migratory and invasive characteristics like 
mesenchymal cells. In case of ovarian carcinoma, the cancerous cells disseminate into the 
peritoneal cavity and can spread to other sites through ascites. Once at a secondary site suitable 
for growth, the process of MET enables them to adhere to the cells at the site and to start 
proliferating again, eventually invading the new site and establishing colonies128. Multiple cellular 
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and molecular markers associated with EMT in EOC cells have been identified. A common feature 
in majority of carcinomas is the loss of cell-cell adhesion and an increase in their migration and 
invasion capabilities34. This is in part due to the loss of E-cadherin, which maintains epithelial cell 
structure by controlling their polarity51,52. Downregulation of E-cadherin at the genetic level is 
attributed to mutations, epigenetic modifications, and altered transcription factor activity, and post-
translationally, E-cadherin is subject to increased degradation in cells undergoing EMT46,53. 
Transcription factors (TFs) that negatively regulate CDH1 (E-cadherin) expression and are 
upregulated in EOC include Snail, Slug, and SIP145. In addition, an increase in the levels of many 
growth factors has been shown to be upregulated, which also contribute to EMT. Transforming 
growth factor-β (TGF-β), epidermal growth factor (EGF), hepatocyte growth factor (HGF), 
endothelin-1 (ET-1), and bone morphogenetic protein 4 (BMP4) have all been found to drive EMT, 
although their contribution is not equal and depending on the type of genetic and transduction 
pathway alterations in each EOC case they show differential effects46. 
 
1.3: Cyclin G2 
1.3.1: Discovery of G Type Cyclins 
As with most of our subjective and imperfect attempts to classify nature in order to simplify 
its study for ourselves, and as more mammalian cyclins were discovered, we learned that not only 
all cyclins do not promote cell cycle progression, but there are those that have the exact opposite 
effect. Enter G type cyclins. The serendipitous discovery of G type cyclins in 1993 came about as 
Tamura and his colleagues set to screen a rat fibroblast cDNA library with a mixture of c-src kinase 
domains as probe54. A year later, it was shown that this new cyclin’s mRNA was upregulated in 
response to gamma irradiation of cells as a transcriptional target of p5355. Finally, in 1996 two 
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distinct G type cyclins in murine and human cells were cloned: cyclin G1 and its homologue cyclin 
G2, encoded by CCNG1 and CCNG2, respectively6. These two cyclins share 53% primary 
sequence and cyclin G2 and cyclin A, the closest relative of G type cyclins, are 26% similar in 
their amino acid sequence6.  
 
It soon became clear that cyclin G1 mRNA was constitutively active throughout the cell 
cycle, but that of cyclin G2 showed oscillating behaviour with peak expression at late S phase6. Of 
more interest is the negative effect of cyclin G2 on cell cycle progression, which will be discussed 
later. Together with cyclin I, they now constitute the unconventional G type cyclin group. All three 
are highly expressed in terminally differentiated tissues; cyclin G1 mRNA is abundant in cardiac 
and skeletal muscle cells and cyclin G2 and I are present at high levels in cerebellum56. Unlike 
cyclin G1 which is a transcriptional target of p5355,57, cyclin G2 expression is p53-
independent6,10,15,58, but its negative effect on cell cycle progression is at least partially mediated 
through the activity of p5359. Despite the homologous nature of cyclin G1 and cyclin G2, their 
distinct transcriptional response to p53, differential regulation during development, and mRNA 
expression patterns during the cell cycle, it is safe to assume that these two proteins play different 
and non-overlapping roles at the cellular as well as organismal levels. An additional structural 
difference between cyclin G1 and cyclin G2 is the lack of a distinct destruction box or PEST 
sequence in cyclin G1, whereas cyclin G2 harbours a PEST motif at its C-terminal, making it 46 
amino acids longer than cyclin G16. The function and significance of PEST sequence are discussed 
later. Overexpression of cyclin G2 has been shown to exert a robust cell cycle halt in a myriad of 
cell types (Table 2), and consistent with this, cyclin G2 mRNA is significantly upregulated in 
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quiescent cells and its levels rapidly drop upon re-entry into the cell cycle60, as well as apoptotic 
cells such as in negatively selected self-reactive T cells15. 
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Table 2: Cell lines in which overexpression of cyclin G2 halts the cell cycle 
Cell line Reference number 
 
CHO 
 
 
56, 59 
 
GES-1 
 
 
61 
 
HCT116 
 
 
62 
 
HEK293 
 
 
56 
 
HeLa 
 
 
63 
 
MCF7 
 
 
64, 65 
 
Murine B cell lines 
 
 
15 
 
Murine splenic B cells 
 
 
66 
 
OV2008 
 
 
67 
 
SCC15 
 
 
68 
 
SGC-7901 
 
 
69 
 
SKBr3 
 
 
64 
 
U2OS 
 
 
59 
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1.3.2: Structural Features of Cyclin G2 
 
Positioned at 4q21.1 in the human genome, CCNG2 encodes a 344-amino acid long protein 
weighing ~39 kDa. Presented in Figure 2 are the structural features of cyclin G2 protein. The N-
terminal half of cyclin G2 harbours its cyclin box stretching from residues 55-165 (Figure 2). 
Although formation of CDK-cyclin complexes relies on the presence of cyclin box10, as of today 
no evidence for a cyclin G2-binding CDK is available, despite its overall similarity to cyclin A, 
which can form complexes with both CDK1 and CDK2. Even more interestingly, the few bona 
fide binding partners of cyclin G2, namely PP2A56, PPARγ70, and cortactin71 bind this protein 
almost completely independent of the cyclin box residues, indicating the existence of novel 
functions of this domain that are yet to be identified.  
 
In its C-terminal half, cyclin G2 contains a PEST domain, stretching from residues 281-
334. The PEST hypothesis was introduced three decades ago72, stating that most unstable proteins 
whose intracellular half-lives are ≤ 2 hours, harbour a stretch of amino acids rich in proline (P), 
glutamic acid (E), serine (S), and threonine (T), and that harbouring these residues in a small 
cluster is involved in rapid degradation and therefore short half-lives of those proteins. Consistent 
with this hypothesis, published data from our lab has demonstrated that cyclin G2 PEST domain 
does indeed contribute to the overall instability of cyclin G2 protein and its partial or full deletion, 
significantly protects cyclin G2 from degradation by the proteasome machinery67. PEST domain 
has also been proposed to be involved in calpain-mediated protein degradation as in the cases of 
IkBα73 and ABCA174. It is worth mentioning that no conserved sequence or motif has been 
proposed to indicate a bona fide PEST domain, but this is rather determined through calculating 
the PEST score for any stretch of amino acids19,72.  
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In addition, cyclin G2 has two LxxLL motifs: 17-LLGLL-21 and 224-LEILL-22870. 
LxxLL is a short motif that facilitates many protein-protein interactions and is especially involved 
in modulating transcription through its presence in several transcription cofactors75. Finally, 
following the initial cloning of Cyclin G2 and interrogation of its primary sequence, it was shown 
to contain an 282-NxxY-285 motif similar to that of EGFR’s auto-phosphorylation site capable of 
binding to Shc phosphotyrosine-binding domain6. However, as of today no evidence of direct 
phosphorylation of cyclin G2 on its Y285 has been presented. 
 
1.3.3: Function and Binding Partners of Cyclin G2  
Protein phosphatase 2A (PP2A) was the first bona fide binding partner of cyclin G2 to be 
identified56. PP2A is a versatile serine/threonine phosphatase76, involved in a wide range of 
seemingly unrelated cellular functions such as cell cycle regulation, signal transduction, 
translational control, and endosome trafficking77-81. Active PP2A is a trimeric complex comprised 
of scaffolding, regulatory, and catalytic subunits designated as A, B, and C subunits, respectively56. 
The scaffolding and catalytic subunits each have two isoforms, and the regulatory subunit which 
controls PP2A substrate recognition and subcellular localization comes in more than sixteen 
different types, giving PP2A its broad involvement in cellular processes56. The minimal 
requirement of residues of cyclin G2 for direct association with PP2A are 142-241, and this 
complex formation seems to take place through replacing the scaffolding subunit of active PP2A 
since cyclin G2-PP2A complexes have been shown to contain both regulatory and catalytic 
subunits, but never the scaffolding56. In this respect, it is tempting to think of cyclin G2 not only 
as an alternative scaffolding subunit for the regulatory and catalytic ones to bind to, but possibly 
as having novel regulatory effects on the function(s) of PP2A. Overexpression of cyclin G2 and 
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its direct association with PP2A results in rapid accumulation of cyclin G2 at the centrosomes59 as 
well as halting of the cell cycle, with a significant increase in the population of cells in G1, unable 
to proceed to S phase56. Ectopic expression of cyclin G2 also results in the formation of aberrant 
nuclei and an increased resistance of microtubules to degradation, which are indicative of of 
defective mitotic and/or cytokinetic processes56,59. Strikingly, overexpression of only the last 100 
residues of cyclin G2’s C-terminal is sufficient to halt the cell cycle59, suggesting the presence of 
mechanisms other than direct binding to PP2A for halting of the cell cycle.  
 
Cyclin G2 is also involved in adipogenesis through direct interaction with peroxisome 
proliferator-activated receptor γ (PPARγ)70. Cyclin G2-PPARγ complex drives the expression of 
adipose-specific genes such as aP2, FATP-1, and LPL82,83. Residues 223-344 of cyclin G2 are 
involved in this binding and of interest is that this binding happens in the same region where 
PPARγ also binds its ligand70. Even though in this scenario cyclin G2 can be thought of as a 
transcription cofactor, none of its LxxLL motifs are involved in binding to PPARγ and mutational 
analysis of those sites (LLGLL→LFAAL and LEILL→LFAAL) revealed no discernable effect on 
the downstream activation of PPARγ target genes70. A more detailed map of the residues involved 
and possibly new protein-protein interaction motifs remain to be elucidated.  
 
A cohort of in vivo as well as in vitro studies recently performed in our lab have broaden 
our understanding of the anti-tumour effects of cyclin G2 in different EOC-derived tumour cells, 
shedding more light on the role(s) of cyclin G2 in tumourigenesis. The broad range of studies 
ranging from the use crude cell lysates to using animal models support the view that cyclin G2 is 
a negative regulator of cancer cells’ growth and proliferation15. To list the highlights of these recent 
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findings, overexpression of cyclin G2 in these cells reduced their proliferation, migration, 
invasion, and spheroid formation, all of which are directly related to the aggressiveness of EOC 
tumours84. In animal models injected with EOC-derived cancer cells the tumour sizes were 
inversely proportional to the presence of ectopically expressed cyclin G2. Of more directly 
applicable results to therapeutic solutions was that it was shown cyclin G2 inhibits EMT in these 
cells and this was shown to be through significant reduction of Wnt/β-catenin signal transduction 
pathway at the cellular and molecular levels. As it was mentioned before, EMT is a crucial step 
towards cancer cells becoming more migratory and aggressive and losing their anchorage 
dependence and can freely migrate and invade near or far tissues in the body, a characteristic of 
stage III and IV of metastatic EOC cases41. Finally, in glioblastoma cells cyclin G2 directly 
interacts with cortactin and this association leads to phosphorylation of cortactin. Interestingly, 
cyclin G2 is a positive factor in expansion of glioblastomas, especially under hypoxic conditions, 
where cyclin G2 levels are increased71.  
 
Figure 2 demonstrates the regions of cyclin G2 that are involved in biding to its partners. 
It is worth noting that all known binding partners of cyclin G2 associate with the protein through 
the regions present in the C-terminal half of the protein, and the roles of cyclin G2 N-terminal half 
remains open for further investigation. 
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Figure 2: Schematic representation of cyclin G2 protein, its verified domains, and binding 
regions to its partners. The C-terminal half of cyclin G2 corresponds to the binding regions of its 
various partners, through which it exerts its various effects in the cell. The C-terminal PEST 
domain (blue) of cyclin G2 has been shown to be involved in its degradation via proteasome 
machinery as well as proteolytic activity of calpains. 
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1.3.4: Regulation of Cyclin G2 
The big picture of cyclin G2 regulation at transcriptional as well as translational levels is 
painted by downregulation in response to growth stimulatory factors and an upregulation when 
growth and proliferation are impeded, consistent with high levels of cyclin G2 mRNA in quiescent 
cells and its power to halt cell cycle progression (Table 1). CCNG2 promoter has binding sites for 
FOXO3a, a member of the forkhead box (FOX) transcription factors (TFs), which positively 
regulates the expression of cyclin G260,66,85. Phosphoinositide 3-kinase-Akt (PI3K-Akt) pathway 
can phosphorylate FOXO3a, leading to its nuclear exclusion and inactivity as a TF, and therefore 
PI3K-Akt activity is at least partially involved in downregulation of cyclin G2 expression60,64. In 
fact, inhibition of PI3K results in dephosphorylation of FOXO3a, which is then able to translocate 
to the nucleus to drive the expression of cyclin G285. Within the same line of reasoning, findings 
from our lab showed that binding of Nodal, a member of the TGF-β superfamily, to its receptor 
(ALK7) slows the proliferation of ovarian cancer cells86 and further investigation provided 
evidence that CCNG2 was amongst the genes that were upregulated as a consequence of this 
interaction85;  activation of ALK7 results in direct interaction between Smad proteins and FOXO3a 
and this complex induces transcription of CCNG2 by binding to its promoter. Activation of 
canonical Smad pathway downstream of ALK7 activation87, and their ability to inhibit PKB 
activity fits nicely into the big picture of cyclin G2 regulation in the context of PI3K-Akt-FOXO3a 
regulatory network.  
 
Following the trend of cyclin G2 downregulation in response to growth stimulatory signals, 
overexpression of the receptor HER2 in breast cancer cells resulted in a significant downregulation 
of CCNG2 mRNA and antibody-mediated blocking of HER2 led to a rapid accumulation of cyclin 
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G2 in the nucleus64. Genotoxic stresses which lead to DNA breaks lead to rapid elevation of cyclin 
G2 levels followed by a G1/S checkpoint activation. Under these conditions, cyclin G2 is recruited 
to the centrosomes where it degrades CDK2 in a p53-dependent manner. DNA damage and cyclin 
G2 upregulation also lead to phosphorylation and activation of Chk2, which then halts the cell 
cycle62.  
 
Cyclin G2 is also negatively regulated in response to a variety of growth stimulatory 
factors. For instance, estrogen-occupied estrogen receptor (ER) can form a complex with Sp1, 
which can then directly bind to cyclin G2 promoter and prevent its transcription by removing RNA 
polymerase II88. Similarly, insulin and its analogue, X10, as well as insulin-like growth factor 1 
(IGF-1) also downregulate cyclin G2’s both mRNA and protein levels89. In our lab we have 
demonstrated that stimulating cells with EGF leads to rapid degradation of cyclin G2 protein, and 
therefore have provided evidence for regulatory effects of EGFR signalling on cyclin G2. The 
details of this process remain to be identified and provide novel and exciting research 
opportunities. As mentioned before, cyclin G2 is also subject to degradation by the proteasome 
machinery and the presence of its full length C-terminal PEST domain is inversely proportional to 
the stability of the protein, indicating that cyclin G2 must be under tight regulation and go through 
rapid turnover in cells67. Our lab has also shown that cyclin G2 is a target of calpain-mediated 
proteolysis in different cell lines, offering new insight into cyclin G2 regulation at protein level. 
 
1.3.5: Cyclin G2 and Cancer 
Considering the bigger picture of cyclin G2 regulation and the type of cellular functions it 
is involved in, it should not come as a surprise that CCNG2 is significantly downregulated in a 
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variety of malignancies including ovarian85, breast90,91, oral68, gastric92, thyroid93, esophageal94, 
prostate95, kidney96 and colorectal97 cancers. To add more context to this, the levels of cyclin G2 
are inversely proportional to the stage of the primary tumours and poorly differentiated carcinomas 
show lower levels of cyclin G2 compared to well-differentiated samples98. Published work from 
our lab has provided evidence for significantly lower levels of CCNG2 expression in EOC cells 
compared to normal ovarian surface epithelium84. In addition, cyclin G2 expression is upregulated 
in response to anti-tumour agents, which cause cell cycle arrest, consistent with the previous 
findings on cyclin G2 effect on cell cycle, growth, and proliferation (Table 2). Similarly, cyclin 
G2 has recently been shown to inhibit EMT processes in ovarian cancer-derived cell lines by 
attenuating Wnt/β-catenin signalling84. Taken together, it is not surprising that two recent studies 
have suggested that levels of CCNG2 can be used as a prognostic tool in breast129 and pancreatic 
cancer98. It seems quite feasible that more data from primary tumour samples will enable us to use 
CCNG2 as a more useful prognostic tool in various types of malignancies. 
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1.4: Calpains 
Protein turnover is the collective term given to the processes that ensure the balance 
between the levels of protein synthesis and degradation which cells employ to maintain 
homeostasis. In contrast to the instructions for protein synthesis, which are universally carried out 
by the ribosomal machinery, evolution has equipped cells with different mechanisms to degrade 
proteins, such as ubiquitin-protease pathway (UPP) as well as a very large family of protein-
degrading enzymes known as proteases or peptidases99.  
 
The superfamily of calpains (calcium-dependent papain-like enzymes) consists of 
cytoplasmic cysteine proteases whose activation and function are dependent on the presence of 
and binding to calcium ions100,101. In humans, there are at least 15 genes encoding different 
calpains102, almost half of which are classified as ubiquitous (calpains 1, 2, 5, 7, 10, 13, and 15), 
and the rest are expressed in a more tissue-specific manner (Calpain 3, 6, 8, 9, 11, and 12)101. 
Although specific physiological functions of calpains are not yet very well-defined, the variety of 
diseases where calpain deregulation is documented is a clear indication of the diverse roles calpains 
play in maintaining human health. Alzheimer’s and other neurodegenerative diseases103, 
cataract101, limb-girdle muscular dystrophy type 2A104, type 2 diabetes105, and metastasis in 
cancer106 are among those conditions where calpain malfunction contributes to the disease state. 
Similar to their wide-yet-not-fully-understood physiological roles, at the cellular level too, calpains 
are involved in a myriad of processes such as signal transduction, cell cycle progression and 
proliferation, apoptosis, differentiation, membrane fusion, platelet activation, and of course, 
calcium-regulated processes102,107-110. Interestingly, while most proteases recognize and cut 
consensus primary sequences within their target proteins, calpain substrate recognition is more 
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structurally dependent101,111, even though the primary sequence of their targets are still 
important111. In this way, calpains have been shown to also recognize and cut the bonds between 
domains101 . A consequence of this particular mechanism of proteolysis is that the calpain targets 
are not always fully digested, but instead the resulting fragment(s) can still be biologically active. 
One well-studied case of this type of proteolysis is the digestion of protein kinase C by calpain, 
which results in an active kinase domain whose function is no longer dependent on effector 
molecules or calcium101,112. In this regard, calpains are called bio-modulators because they can 
exert this kind of regulatory effect on their substrates101.  
 
The two conventional and ubiquitous calpain 1 and calpain 2, also known as µ-calpain and 
m-calpain, respectively are the better-studied members of the calpain superfamily. The ‘m’ and 
‘µ’ refer to the [Ca2+] requirements of the two calpains in vitro: micromolar and macromolar, 
respectively113. Both these calpains are heterodimers comprised of a large ~80 kDa catalytic 
subunit and a regulatory ~30 kDa subunit101. The catalytic subunit consists of domains I, IIa and 
IIb, III, and IV, and the regulatory subunit contains V and VI domains. Domains IV and VI 
facilitate the interaction between the two subunits. In the absence of Ca2+ binding, calpain is 
inactive because of the steric hindrances between IIa and IIb domains. Following conformational 
changes upon binding to calcium ions, the two domains interact and form the active catalytic site 
of calpain101. Figure 3 shows the ways through which intracellular calcium concentration 
increases, which in turn lead to activation of calpains. While different genes encode the catalytic 
subunits of calpain 1 and calpain 2 (CAPN1 and CAPN2, respectively), the regulatory subunit is 
encoded by the same gene (CAPN4) and is shared in joining µ-calpain and m-calpain catalytic 
subunits114. ERK, one of the downstream effectors of EGFR signal transduction pathway has also 
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been shown to activate m-calpain through phosphorylation115. Endogenously, calpain inhibition is 
carried out by the cytosolic calpain inhibitor, calpastatin116. There is also evidence for inhibition 
of m-calpain activity upon becoming phosphorylated by protein kinase A117. Various commercial 
short peptide as well as nonpeptidic calpain inhibitors are available, but their specificity is not very 
high101,107,118.  
 
Preliminary data from our lab suggest that cyclin G2 is a target for calpain 1 and calpain 2 
in vitro in different human ovarian cancer cells. In addition, we also have provided evidence that 
the PEST domain of cyclin G2 is not only involved in its degradation via the ubiquitin-proteasome 
pathways (UPP), but that the same trend is observed with respect to degradation by calpain as well; 
truncated or fully deleted PEST domain increases stability of cyclin G2 compared to when the full-
length PEST domain is present. Overexpression of HER2 in breast cancer cells leads to 
degradation of IκBα in a calpain-dependent manner73. IκBα is similar to cyclin G2 in size and it 
too harbours a C-terminal PEST domain, and so interesting parallels can be drawn from the studies 
of IkBα degradation.  
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Figure 3: Activation of calpain as a consequence of increasing intracellular calcium 
concentration. Intracellular [Ca2+] increases in response to ligand- or light-activated calcium 
channels (green). Alternatively, G-protein coupled receptor (GPCR) activation as well as other 
signals that promote the release of intracellular reserves of calcium also cause an increase in 
intracellular [Ca2+]. Upon binding to calcium ions, calpain goes through conformational changes, 
exposing its catalytic domain for recognition and proteolysis of its protein substrates. Structural 
features of this activation process are discussed in the text. 
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1.5: Epidermal Growth Factor Signalling 
Epidermal growth factor (EGF) is a short protein which upon binding to its receptor, 
epidermal growth factor receptor (EGFR/ErbB1) induces one of the most diverse signal 
transduction pathways ever discovered and studied119. The formation of ligand-receptor complex 
induces conformational changes in EGFR and brings two inactive subunits together to form dimers 
followed by trans-autophosphorylation of the two subunits on their specific tyrosine residues, 
forming docking sites and activating signals for a myriad of downstream effectors120. EGFR can 
also be activated through binding to its other ligand, transforming growth factor-α (TGFα)121. The 
diversity of the downstream pathways stemming from EGFR activation is also the result of the 
fact that aside from forming homodimers, EGFR can heterodimerize with its three homologues, 
ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4) and the type of ligand bound to these receptors 
determines the resulting heterodimers and the downstream pathways they activate120. ErbB2 has 
no known ligand, but its association with other members of the ErbB family and its subsequent 
kinase activity has been well established122. EGF is a mitogen whose signal is translated to an 
leveling up of the processes such as proliferation, differentiation, and survival as well as an 
increase in protein synthesis123,124. Overall, EGFR signalling is associated with cell survival and 
enhanced proliferation. Given the nature of these signals and the different ways ErbB family 
members can form active dimers, it comes as no surprise that dysregulated ErbB signalling is 
prevalent in many types of cancer120. The enhanced activity of ErbB family can be the result of 
gain-of-function mutations as well as receptor and/or ligand overexpression in a myriad of cell and 
cancer types124,130. 
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In our lab we have shown that stimulating ovarian cancer cells with EGF leads to rapid 
degradation of cyclin G2 protein, consistent with our overall knowledge of the negative effects of 
cyclin G2 on cell cycle and tumour formation. We have additionally provided evidence that 
inhibition of EGFR by Tyrphostin AG 1478 protects cyclin G2 from degradation in the presence 
or absence of EGF. Taking into consideration that EGFR signalling can activate both calpain 
activity as well as PI3K-Akt signalling pathway, we show new connections between EGF 
signalling and cyclin G2 regulation both at transcriptional and translational levels. 
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Figure 4: Simplified EGFR signalling pathways. EGFR (red) undergoes conformational 
changes upon binding to EGF (black), which facilitate the formation of EGFR homodimers. The 
cytoplasmic domains of each monomer transphosphorylates the other on a number of tyrosine 
residues. The phosphorylated tyrosine residues serve as docking sites for various proteins, which 
then relay the signal through four main pathways: PI3K/AKT (blue), STAT (green), MAPK/ERK 
(orange), and PLCγ/PKC (yellow). The genes activated downstream of EGFR promote cellular 
proliferation as well as migration and invasion capabilities of the cell while suppressing apoptosis 
and other growth inhibitory signals. For simplicity, only the better-known proteins from each 
pathway have been selected to be shown. 
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1.6: Rationale, Hypothesis, and Objectives of Present Study 
Our lab has provided evidence that the interaction of Nodal with its receptor, ALK7, results 
in the halting of human ovarian cancer cell proliferation86. Further studies identified CCNG2 
(cyclin G2) was amongst the upregulated genes as the result of Nodal-ALK7 interaction and it was 
also partially responsible for exerting the aformentioned antiproliferative effect on those cells85. 
Unlike canonical cyclins which promote cell cycle progression and cellular proliferation15, ectopic 
expression of cyclin G2 can result in halting of the cell cycle (references listed in Table 2). More 
recently, our lab showed that cyclin G2 has anti-tumour effects in vivo and that its expression 
levels are significantly lower in human epithelial ovarian canrcinoma84. Other lines of evidence 
have shown significant downregulation of cyclin G2 in a variety of other cancers as well98. Taken 
together, it is suggestive that downregulation or loss of cyclin G2 might be one of the contributing 
factors to the development of EOC. Given the severity of EOC and poor prognosis of patients, and 
the recent discoveries demonstrating the role of CCNG2 in the development of ovarian cancer, it 
is important to investigate the mechanisms which govern degradation of cyclin G2 in these cells.  
 
Preliminary data from our lab showed that in human ovarian cancer cells, cyclin G2 is 
quickly degraded, and this rapid turnover is due to the presence of a PEST sequence in the C-
terminal end of cyclin G2. PEST sequences serve as regulatory motifs in proteins destined for 
degradation by both the proteasome pathway131 as well as calpain-mediated proteolysis73. Our lab 
has demonstrated that cyclin G2 is indeed degraded through the UPP. Additional data found in our 
lab suggested that degradation of cyclin G2 was connected to intracellular calcium levels as well 
as the presence of calcium in crude cell lysate. Taken together, this suggested a role for calpain in 
meditating the degradation of cyclin G2. Additional data showed a role for phosphorylation as a 
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necessary step in cyclin G2 degradation and results from other work in our lab pointed us to the 
involvement of EGFR signalling in destruction of cyclin G2 protein. 
 
Considering our findings about cyclin G2 in human ovarian cancer cells, we hypothesize 
that i) cyclin G2 can be degraded by calpain in these cells, and that ii) EGFR signalling is at least 
partially involved in the degradation of cyclin G2. The focus and purpose of the present study were 
to unravel more details that govern the rapid turnover and degradation of cyclin G2 in human 
ovarian cancer cells. The overall objective of this project was to show the involvement of calpain 
in the degradation of cyclin G2 and the role of growth stimulatory pathways on the fate of the 
protein. More specifically, we investigated i) degradation of cyclin G2 in vitro by calpain and ii) 
the involvement of EGFR signalling in cyclin G2 turnover, a novel aspect of cyclin G2 regulation. 
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Chapter 2: Materials and Methods 
2.1: Cell Lines and Cell Culture 
All original and modified cell lines were incubated at 37°C in humidified atmosphere 
containing 5% CO2. Unless otherwise stated, all media were supplemented with 10% heat-
inactivated fetal bovine serum (incubated at 56°C water bath for 30 minutes) and 1% Penicillin-
Streptomycin (P/S) cocktail for cell passage or initial seeding for downstream treatments. Cells 
were passaged when reached 80-90% confluency and were seeded at 3x105 cells/well of 6-well 
plates or 1x106 cell/10-cm plates. For stably transfected cells with pBABE-puro empty vector or 
the vector containing CCNG2 cDNA, 10 µg/ml puromycin was added to the media to select for 
cells retaining the exogenous DNA constructs. Table 3 lists the cell lines and their tissue origins 
as well as the media type and supplements used for this project. Cells stably expressing the empty 
vector (EV) or FLAG-CCNG2 construct were generated by Dr. Stephanie Bernaudo in our lab84. 
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Table 3: Original and modified cell lines, tissue origins, and respective media and 
supplements 
Cell Line Tissue Origin Media + Supplements 
 
OV2008 
 
 
Human cervical carcinoma (ATCC)a 
RPMI-1640b + 10% FBSc + 
1% P/Sd 
 
OV2008-EV 
OV2008 cells stably transfected with 
empty pBABE-Puro vector 
RPMI-1640 + 10% FBS + 
1% P/S + 10 µg/ml 
puromycine 
 
OV2008-CG2 
OV2008 cells stably transfected with 
pBABE-Puro harbouring 3XFLAG-
CCNG2 cDNA 
RPMI-1640 + 10% FBS + 
1% P/S + 10 µg/ml 
puromycin 
 
SKOV3 
 
 
Human ovarian carcinoma (ATCC) 
DMEMf + 10% FBS + 1% 
P/S 
 
SKOV3.ip1g 
 
SKOV3 cells intraperitoneally injected 
into mice and recovered afterwards 
 
DMEM + 10% FBS + 1% P/S 
 
SKOV3.ip1-EV 
SKOV3.ip1 cells stably transfected with 
empty pBABE-Puro vector 
DMEM/McCoyh + 10% FBS 
+ 1% P/S + 10 µg/ml 
puromycin 
 
SKOV3.ip1-CG2 
SKOV3.ip1 cells stably transfected with 
pBABE-Puro harbouring 3XFLAG-
CCNG2 cDNA 
DMEM/McCoy + 10% FBS 
+ 1% P/S + 10 µg/ml 
puromycin 
 
ES2 
 
 
Human ovarian carcinoma (ATCC) 
McCoy’s 5A + 10% FBS + 
1% P/S 
 
ES2-EV 
ES2 cells stably transfected with empty 
pBABE-Puro vector 
McCoy’s 5A + 10% FBS + 
1% P/S + 10 µg/ml 
puromycin 
 
ES2-CG2 
ES2 cells stably transfected with pBABE-
Puro harbouring 3XFLAG-CCNG2 
cDNA 
McCoy’s 5A + 10% FBS + 
1% P/S + 10 µg/ml 
puromycin 
 
HEYi 
 
 
Human ovarian carcinoma 
 
DMEM + 10% FBS + 1% P/S 
a American Type Culture Collection (Manassas, VA, USA), bRPMI-1640: Roswell Park Memorial 
Institute medium-1640 (GE HyClone, Logan, UT, USA, SH30027.02), cFBS: fetal bovine serum 
(Life Technologies, Burlington, ON, Canda, 12483-020), dP/S: Penicillin-Streptomycin (Multicell, 
450-201-EL), ePuromycin (InvivoGen, ant-pr), fDMEM: Dulbecco’s Modified Eagle Medium (GE 
HyClone, Logan, UT, USA, SH30243.01), gSKOV3.ip1 cells were obtained from Dr. Mien-Chie 
Hung (MD Anderson Cancer Centre, Houston, TX, USA), hMcCoy’s 5A (Sigma-Aldrich, 
Oakville, ON, Canada, M4892), iHEY cells were obtained from Dr. Ted Brown (Mount Sinai 
Hospital, Toronto, ON, Canada). 
 
 
 33 
2.2: Transient Transfection 
Plasmid DNA for transient transfections was purified from 100-150 ml overnight cultures 
of E. coli DH5α grown in LB media with 100 µg/ml ampicillin, using PerfectPrep Endofree Maxi 
Kit (5 Prime, 2300120). The concentration and purity of each preparation was measured using a 
NanoDrop2000c instrument (Thermo Scientific). Only samples with A260/A280 ratio of ≥1.8 
were used for subsequent transient transfections. Cells of 70-90% confluency were transiently 
transfected overnight (16-18 h) with 3µg of DNA per well of 6-well plates and 7 µg of DNA per 
10 cm plates, using Lipofectamine 2000 (Invitrogen, 11668019) following the manufacturer’s 
instructions with the following deviation: 1/5 of the total volume of the media added to cells 
consisted of the mixture of plasmid DNA and Lipofectamine 2000 in OMEM (Opti-MEM®, 
Invitrogen, 31985070) and the rest was comprised of media in which the cells were originally 
cultured in, supplemented with 1% P/S and no serum. After overnight transfection, the transfection 
mixture was first removed, followed by the appropriate treatment. Per case treatments are 
described in the Results section. 
 
 
 
2.3: Cell Lysate Preparation and Western Blotting 
Cells were washed with room temperature 1X PBS pH 7.4, and collected and lysed in 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% 
sodium deoxycholate, 1% NP-40, 0.1% SDS) supplemented with protease inhibitor cocktail 
(Thermo Scientific, 88266). Where applicable, total protein concentration of cell lysate was 
measured using Pierce® BCA Protein Assay (Thermo Scientific, 88266). The cell lysate was then 
mixed with 5X SDS sample buffer (0.25 M Tris-HCl pH 6.8, 0.25% bromophenol blue, 0.5 M 
DTT, 50% glycerol, 10% SDS) and boiled for 5-10 minutes. Protein ladder and equal amounts of 
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protein samples were then loaded onto the wells of 12% SDS-polyacrylamide gels (recipe in Table 
4) placed in 1X Tris-Glycine running buffer (0.3% Tris, 1.44% glycine, 1% SDS) and proteins 
were separated by electrophoresis at room temperature (at 100V until samples reached the 
separating gel, followed by 150V until desired separation was achieved, judging by the ladder 
markers). The contents of each gel were electrotransferred at 100V for 60 min on ice onto a 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad, 162-0177) in transfer buffer (10% Tris-
glycine running buffer, 20% methanol). The membranes were then blocked using 5% skim milk 
(no name®, 20052038_EA) dissolved in TBS while gently rocking at room temperature for 1 hour. 
Each membrane was then incubated overnight at 4°C with the appropriate primary antibody 
prepared in either 5% skim milk or BSA (BioShop, ALB001.100). The following day, each 
membrane was washed 3 time for 10 minutes with TBS-T, followed by incubation with HRP-
conjugated anti-mouse or anti-rabbit IgG at room temperature. The membranes were washed again 
3 times for 10 minutes with TBS-T and then incubated with HRP substrate (Millipore, 
EBLUC0500) for 3-4 minutes. Antigen-antibody complexes were visualized using an ECL 
detection system and photo-sensitive film developed in a Konica Minolta SRX-101A system 
(Konica Minolta Medical Imaging) or using a MicroChemi scanner and GelCapture Chemi 
analysis software (DNR Bio-Imaging Systems Ltd.). Where necessary, the band signals were 
quantified using Image Studio Lite 3.1 (LI-COR Inc.).   
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Table 4: SDS-polyacrylamide stacking and resolving gels recipes 
Gel layer dH20 
(ml) 
30% 
Acrylamide 
(ml) 
1.5 M 
Tris, pH 
8.6 (ml) 
1.0 M 
Tris, pH 
6.8 (µl) 
10% 
SDS (µl) 
10% 
APS (µl) 
TEMED 
(µl) 
 
Resolving 
 
 
3.3 
 
4 
 
2.5 
 
– 
 
100 
 
50 
 
10 
 
Stacking 
 
 
1.9 
 
0.320 
 
– 
 
315 
 
25 
 
10 
 
3 
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Table 5: Antibodies used for western blot analysis 
Antibody Company Species Dilution 
 
FLAG 
 
 
Sigma 
 
Mouse 
 
1:1000 
 
GAPDH 
 
 
Santa Cruz 
 
Mouse 
 
1:10000 
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2.4: In Vitro Calcium-Induced Degradation Assay 
SKOV3.ip1 and ES2 cells stably transfected with FLAG-CCNG2 construct were washed 
with room temperature PBS and lysed under non-reducing and non-denaturing conditions in RIPA 
buffer containing 0, 0.5, or 5 mM CaCl2 and incubated for 60 and 120 minutes at room temperature 
(~22°C) or at 37°C. Aliquots of each reaction were mixed with 5X SDS sample buffer and 
immunoblotted with anti-FLAG antibody to detect cyclin G2 levels. 
 
 
2.5: In Vitro Calpain-Induced Degradation Assay 
Studying the effects of calpain on cyclin G2 degradation: SKOV3.ip1, ES2, and HEY cells 
were transiently transfected with FLAG-CCNG2 construct overnight as described before. The next 
day cells were washed with room temperature PBS and lysed under non-reducing and non-
denaturing conditions in calpain degradation buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 1 
mM DTT, 0.5% Triton-X). Cell lysate total protein concentration was measured using Pierce® 
BCA Protein Assay (Thermo Scientific, 88266). From each cell lysate, five aliquots each 
containing 480 µg total protein were taken and incubated with 0 or 500 µM CaCl2, and in the 
presence or absence of 12 units of calpain-1 (porcine erythrocytes, Calbiochem, 208712) as well 
as a calpain inhibitor, calpeptin (Calbiochem, 03-34-0051) and incubated in a 30°C water bath for 
1 hour. Reactions were stopped by adding 5X SDS sample buffer and subsequently subjected to 
western blot analysis with anti-FLAG antibody to monitor the levels of cyclin G2. 
  
Investigating the effects of EGFR inhibition on calpain-mediated degradation of cyclin G2: 
SKOV3.ip1, ES2, and HEY cells were transiently transfected with FLAG-CCNG2 construct 
overnight as described before. The following day transfection mixture was removed and cells were 
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treated with 10 µM of an EGFR inhibotr, Tyrphostin AG 1478 (Sigma-Aldrich, T4182) or DMSO 
vehicle in serum-free media for 30 min. Cells were washed with room temperature PBS and lysed 
under non-reducing and non-denaturing conditions in calpain degradation buffer. Total protein 
concentration of each cell lysate was determined using Pierce® BCA Protein Assay. Aliquots from 
cell lysates each containing 480 µg total protein were mixed with 1 µM Tyrphostin AG 1478 or 
1:1000 DMSO (Sigma, D4540), in the presence or absence of calpain-1 and incubated in a 30°C 
water bath for 1 hour. Reactions were stopped by addition of 5X SDS sample buffer and western 
blot analysis was carried out using anti-FLAG antibody to observe the levels of cyclin G2. 
 
 
2.6: Kinase Inhibitor Library Assay 
SCREEN-WELL® kinase inhibitor library (Enzo Life sciences, BML-2832-0500) and 
EGFR kinase inhibitor, Tyrphostin AG 1478 (Sigma, T4182) stocks were prepared in DMSO at 
10 mM. The stocks were diluted to working concentrations in the appropriate cell media containing 
antibiotics in the absence of serum. Cells were incubated with the appropriate kinase inhibitor or 
DMSO control plus 10 µg/ml cycloheximide (Sigma) to block protein de novo synthesis for 30-
120 minutes. 10 µM MG-132 (Selleckchem, S2619), a proteasome inhibitor was included as 
positive control when cyclin G2 was protected from degradation. Table 4 lists the kinase inhibitors 
used in these assays. 
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Table 6: Kinase inhibitors, their targets, and working concentrations (all stocks 10 mM) 
Inhibitor Name/ID Target S/T/Y* Kinase Concentration Used (µM) 
Tyrphostin AG 1478 EGFR Y 10 
Wortmannin PI3K – 1 
PP2 Src Y 10 
BML-257 Akt S/T 10 
Rapamycin mTOR S/T 0.01 
GW5074 cRAF S/T 1 
Y-27632 ROCK S/T 10 
ZM449829 JAK3 Y 1 
5-Iodotubercidin CK1 S/T 10 
Apigenin CK2 S/T 10 
5-Iodotubercidin ERK S/T 10 
Hypericin PKC S/T 10 
Piceatannol Syk Y 10 
SU-4312 Flk1 Y 10 
SP-600125 JNK S/T 50 
PD-98059 MEK S/T 50 
SB-203580 p38 S/T 10 
*S: serine, T: threonine, Y: tyrosine 
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2.7: Epidermal Growth Factor Treatments 
Lyophilized recombinant human EGF (Invitrogen, PHG0311) was reconstituted in sterile 
PBS pH 7.4 to a final concentration of 10 mg/ml as the stock. Unless indicated, cells were serum-
starved for ~18 hours overnight, followed by a 30-minute treatment with 10 µg/ml cycloheximide 
(CHX) and subsequent addition of media with antibiotics in the absence of serum containing 20 
ng/ml EGF to each well or plate for 1-2 hours. Treatment with 10 µM MG-132 was included as 
positive control for cyclin G2 protection. 
 
2.8: Statistical Analyses 
Results are expressed as mean ±SEM. One-way analysis of variance (ANOVA) was used 
to determine the difference between multiple groups in each experiment and Tukey’s post-hoc 
analysis was utilized to decide the statistical difference between the specific groups. GraphPad 
Prism 6.0 software was used to conduct statistical testing and significance was defined as p<0.05. 
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Chapter 3: Results 
3.1: Cyclin G2 is an Unstable Protein with a Short Half-Life 
A few years ago, our lab demonstrated the unstable nature of cyclin G2 protein in OV2008 
cells67. However, through profiling a number of cell lines, a more recent study showed that 
OV2008 are actually of cervical cancer origin as opposed to EOC132. Therefore, we started to use 
other EOC cell lines to study the stability of cyclin G2 in those cells. Where possible, OV2008 
cells were used as a positive control.  
In one series of experiments, OV2008, SKOV3.ip1, and ES2 cells stably transfected with 
a FLAG-CCNG2 construct (stable cells) were used to monitor the stability of cyclin G2 protein. 
After overnight serum starvation and when de novo protein synthesis was blocked by addition of 
cycloheximide (CHX), a significant reduction in the levels of protein were observed at around 1 
hour compared to the start of the experiment (Figure 5A, 5B, 5C). We also tested the stability of 
cyclin G2 in ES2 and HEY cells through transient transfection. To do this, ES2 and HEY cells 
were transiently transfected with a FLAG-CCNG2 construct overnight, with a subsequent 
treatment with 10 µg/ml CHX in serum-free media. Sample collection and analysis were 
performed exactly the same as in the stable cells (Figure 5D, 5E). In both stable and transiently 
transfected cells Western blot analysis and subsequent quantification of the bands demonstrated a 
rapid decline in the levels of cyclin G2 as soon as 1 hour, with the most and least degradation 
observed in ES2 and SKOV3.ip1 cells, respectively. 
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For the rest of the figure and legend please continue to next page. 
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 For the rest of the figure and legend please continue to next page. 
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Figure 5: Cyclin G2 is an unstable protein and is degraded rapidly in human ovarian cancer 
cell lines. (A) OV2008, (B) SKOV3.ip1, and (C) ES2 cells stably expressing FLAG-CCNG2 were 
treated with CHX and samples were taken at the intervals indicated. Transiently transfected (D) 
ES2 and (E) HEY cells were analyzed in the same way. Levels of cyclin G2 at each time interval 
were monitored using western blotting and graphs were generated by quantifying bands as 
previously described. Data represent mean±SEM of three experiments. Differences were 
considered significant at values of p<0.05. 
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3.2: Addition of Calcium Induces Cyclin G2 Degradation in a Concentration-Dependent 
Manner In Vitro 
As mentioned earlier, cyclin G2 harbours a destabilizing PEST domain in its C-terminal, 
which has been shown to enhance cyclin G2 degradation via the proteasome machinery in human 
ovarian cancer cells67. To investigate whether or not cyclin G2 is susceptible to degradation by 
calpain as well, we set up a series of experiments to explore these questions. Since an increase in 
the intracellular concentration of calcium enhances the activity of calpains101, we investigated the 
effect of supplementing crude cell lysate with additional source of calcium to see if this in turn led 
to degradation of cyclin G2. Equal numbers of SKOV3.ip1 and ES2 cells stably expressing FLAG-
CCNG2 were seeded and upon attachment to the plate substrate were collected and lysed. Equal 
amounts of each cell lysate were incubated with lysis buffer containing increasing concentrations 
of CaCl2 and incubated for 1 or 2 hours at 37°C for SKOV3.ip1 cells and 1 hour at 37°C as well 
as room temperature for ES2 cells. Blotting for FLAG to detect levels of cyclin G2 revealed that 
addition of calcium did indeed result in increased degradation of cyclin G2 (Figure 6). 
Additionally, higher concentration (5 mM) of calcium resulted in more degradation of cyclin G2 
compared to when 0.5 mM calcium was present. 
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Figure 6: Addition of calcium causes degradation of cyclin G2 in vitro. (A) SKOV3.ip1 cells 
stably expressing FLAG-CCNG2 were lysed and incubated with increasing amounts of calcium at 
37°C. (B) Stable ES2 cells were lysed and incubated with increasing amount of calcium for 1 hour 
at temperatures indicated. 5 mM CaCl2 caused the most degradation of cyclin G2 in both cell lines. 
  
 47 
3.3: Cyclin G2 is Degraded by Calpain-1 In Vitro 
 Degradation of cyclin G2 in response to addition of calcium in cell lysates prompted us to 
verify if the activity of calpain is in fact at least one driving force behind this phenomenon under 
the experimental conditions. To do this, equal densities of SKOV3.ip1, ES2, and HEY cells were 
transiently transfected overnight with a FLAG-CCNG2 construct and subsequently lysed in calpain 
degradation buffer with or without 0.5 mM CaCl2, active calpain-1, and calpeptin, a calpain 
inhibitor. Western blot analyses (Figure 7) confirmed that in the presence of added calcium, active 
calpain-1 caused a reduction in the levels of cyclin G2 protein. Addition of CaCl2 or calpain alone 
had no obvious effect on cyclin G2 levels as compared to the negative control. Addition of 
calpeptin to cell lysate protected cyclin G2 from degradation by inhibiting the activity of calpain-
1. However, these results should be considered with caution since calpain-1 failed to cause 
degradation of cyclin G2 significantly as shown in Figure 9. 
  
 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
For the rest of the figure and legend please continue to next page. 
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Figure 7: Calpain-1 degrades cyclin G2 in vitro. Various human ovarian cancer cells, (A) 
SKOV3.ip1, (B) ES2, and (C) HEY, were transiently transfected and aliquots of cell lysate were 
incubated with the ingredients as indicated in each panel. When supplemented with extra calcium, 
calpain-1 activity leads to dramatic degradation of cyclin G2 and this process is significantly 
blocked when calpeptin, a calpain inhibitor, is added to the cell lysate. Labels on the left of the 
blots denote the cell line used. Graphs represent mean±SEM (n=3), and the differences were 
considered significant at values of p<0.05. 
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3.4: Inhibition of EGFR Kinase Activity Protects Cyclin G2 from Degradation 
Unpublished data from our lab have demonstrated a role for phosphorylation in the process 
of calpain-mediated proteolysis of cyclin G2 in OV2008 cells. This discovery prompted us to use 
a kinase inhibitor library to find out if cyclin G2 could be protected from degradation when various 
protein kinases were inhibited. Serum-starved OV2008 cells stably expressing a FLAG-CCNG2 
construct were pretreated with a variety of kinase inhibitors for 1 hour, followed by treatment with 
epidermal growth factor (EGF) and CHX for an additional hour or shorter. EGF is able to bind to 
and subsequently induce rapid activation of EGFR and its downstream signalling pathways. 
Western blot analyses showed that cyclin G2 was protected from degradation when EGFR was 
inhibited (Figure 8A). In a similar fashion, but in the absence of EGF, ES2 cells were transiently 
transfected and levels of cyclin G2 were monitored when the cells were treated with different 
kinase inhibitors (Figure 8B). The results suggest that EGFR kinase activity is involved in 
regulation of cyclin G2 degradation, and inhibition of its kinase activity, regardless of the presence 
or absence of EGF stimulation of the cells.  
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Figure 8: Inhibition of EGFR blocks cyclin G2 degradation. (A) OV2008 cells stably 
expressing a FLAG-CCNG2 construct were treated with various kinase inhibitors followed by 
EGF treatment. In the presence of Tyrphostin AG 1478, an inhibitor of EGFR, cyclin G2 was not 
degraded. (B) ES2 cells were transiently transfected with a FLAG-CCNG2 construct, followed by 
treatment with various kinase inhibitors. Inhibition of EGFR protected cyclin G2 protein from 
degradation. Inhibition of Src by PP2 also showed some protective effect. The experiment 
presented in B panel was conducted and the figure was created by Ms. Alina Kopteva. MG-132, 
an inhibitor of proteasome, was included as the control since it protects cyclin G2 from 
degradation. 
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3.5: Effect of EGFR Inhibitor on Calpain-Mediated Degradation of Cyclin G2 
 To further investigate the connection between EGFR activity and calpain-mediated 
degradation of cyclin G2, SKOV3.ip1, ES2, and HEY cells were transiently transfected as 
described before, followed by a 30-minute treatment with Tyrphostin AG 1478, a potent inhibitor 
of EGFR, or vehicle DMSO. Cells were then lysed in calpain degradation buffer and the lysate 
was incubated with Tyrphostin AG 1478 or DMSO in the presence of added calcium to ensure the 
continued inhibition of EGFR. As depicted in Figure 9, inhibition of EGFR resulted in some degree 
of protection against cyclin G2 degradation when cell lysates were incubated with active calpain-
1. However, due to large variation among the experiments, no stastistical significance among 
different treatment groups was observed. Fine-tuning of the experimental conditions can shed more 
light on the connection between EGFR inhibition and calpain-mediated degradation of cyclin G2.  
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For the figure legend please continue to next page. 
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Figure 9: Effects of EGFR inhibition on cyclin G2 degradation by calpain-1. Human ovarian 
cancer cells, (A) SKOV3.ip1, (B) ES2, and (C) HEY, were transiently transfected with FLAG-
CCNG2 construct overnight and treated with an inhibitor of EGFR or DMSO. Lysed cells were 
incubated with active calpain-1 in the presence or absence of EGFR inhibitor. Graphs represent 
mean±SEM (n=3).  
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3.6: EGF Stimulation Leads to Degradation of Cyclin G2 
 According to the results presented here, EGFR seems to play a positive role in degradation 
of cyclin G2 in the human ovarian cancer cells we have used. As we saw earlier, one of the ligands 
that activates EGFR kinase activity if epidermal growth factor (EGF). To study the effects of 
EGFR activation alone on the fate of cyclin G2 in human ovarian cancer cells, cells under 
investigation were serum-starved (except in one case), followed by a treatment of EGF for various 
time lengths as indicated in each figure. 
  
To test the effect of EGF on cyclin G2 degradation, OV2008 and SKOV3.ip1 cells stably 
expressing a FLAG-CCNG2 construct were serum-starved and subsequently treated with 
increasing amounts of EGF for an hour in the presence of CHX. We saw a decline in the levels of 
cyclin G2 after an hour when cells were treated with 20 ng/ml EGF (Figure 10A). To study whether 
the presence of serum has any effect on EGF treatment, SKOV3.ip1 stable cells were treated with 
increasing amounts of EGF in the presence or absence of serum in the media. Western blot analysis 
revealed that the presence of serum had no discernable effect on levels of cyclin G2 (Figure 10B). 
To assay the effect of 20 ng/ml EGF treatment on the levels of cyclin G2 as a function of time, 
ES2 and SKOV3.ip1 stable cell lines were incubated with EGF or MG132, an inhibitor of the 
proteasome machinery, along with their vehicles, plus 10 µg/ml CHX. MG132 was used as positive 
control for protection against degradation as it has been shown that cyclin G2 is a target for 
degradation by the proteasome2. It became obvious that after 2 hours of treatment, levels of cyclin 
G2 had decreased in both cell lines. This decline was much more obvious in ES2 cells, where after 
the first hour, all traces of cyclin G2 were gone, except where cells were treated with MG132. The 
more enhanced degradation of cyclin G2 in these two cell lines corroborates with the results of 
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cyclin G2 stability in various human ovarian cancer cell lines as before. Figure 11 summarizes 
these findings. 
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Figure 10: EGF stimulation causes degradation of cyclin G2. (A) Cyclin G2 was degraded in 
OV2008 and SKOV3.ip1 cells upon EGF stimulation. (B) Presence or absence of serum had no 
effect on cyclin G2 degradation in response to EGF treatment of SKOV3.ip1 cells overexpressing 
cyclin G2.  
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Figure 11: Inhibition of proteasome protects cyclin G2 from degradation. In both ES2 (left 
panel) and SKOV3.ip1 cells stably expressing a FLAG-CCNG2 construct EGF caused cyclin G2 
degradation. MG132, a proteasome inhibitor, which also has inhibitory effects on calpain activity, 
protected cyclin G2 in both cell lines and under different experimental conditions. 
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Chapter 4: Discussion 
Increasing evidence points towards potent negative effects of cyclin G2 on cell cycle 
progression and proliferation. More specifically, and focusing on enhanced capability of cancer 
cells to migrate and invade, our lab has demonstrated that cyclin G2 overexpressing ovarian cancer 
cells had a reduced ability to migrate and invade when compared to the control group. Consistent 
with the effects of cyclin G2 at the cellular level, our lab has also shown that the tumour size in 
mice models was overall smaller when the animals were injected with cells that were 
overexpressing cyclin G2 when compared to the control cells that only expressed the empty vector. 
Looking at the bigger picture, numerous experiments ranging from cultured cells to primary 
clinical samples of tumours show an inverse relationship between the levels of cyclin G2 and the 
stage of cancer. Taking into consideration that cyclin G2 not only can halt the cell cycle, but also 
limit cells’ ability to migrate and invade we can conclude that this protein is involved in not only 
control of cell cycle, but also in cell mobility and anchorage dependence. 
 
As part of the present study, we assayed the stability of cyclin G2 protein in a number of 
human ovarian cancer cells. Degradation of cyclin G2 in cells overexpressing it is visible as early 
as 1 hour, and the levels are barely detectable after 5 hours when de novo protein synthesis was 
blocked by using cycloheximide (CHX). The results are in agreement with the previous findings 
of our lab that cyclin G2 is an unstable protein67. These findings are also in harmony with the 
context of the growth of cancer cells; to bypass the growth inhibitory signals, cancer cells often 
eliminate the anti-proliferative signals both at genetic and protein levels. Knowing the negative 
effects of cyclin G2 on cell cycle progression and its anti-tumour effects it makes perfect sense 
that cyclin G2 is degraded quickly in cancer cells.  
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Since the original proposal of PEST hypothesis72, increasing evidence has shown that 
proteins harbouring PEST domains are indeed short-lived and that their degradation is at least in 
part carried out by the catalytic activity of calpains, a class of proteases whose activation relies on 
the presence of calcium101. When bound to calpain, calcium ion causes a conformational change 
in the protease, leading to its activation. In this study, we demonstrated that calpains play a role in 
regulating cyclin G2 degradation. First, in vitro studies using crude cell lysates of human ovarian 
cancer cells overexpressing cyclin G2 showed that addition of calcium to the cell lysate did in fact 
cause a decrease in the levels of cyclin G2 when compared to the control groups. Second, addition 
of calpain to the cell lysate in the presence of CaCl2 caused a dramatic decrease in the levels of 
cyclin G2. Third, addition of calpeptin, an inhibitor of calpain, reversed the effect of calpain in the 
presence of CaCl2, and protected cyclin G2 from degradation. 
 
Adding to our understanding of this process, unpublished data from our lab also shows that 
phosphorylation is a required step in degradation of cyclin G2 by calpain; treatment of cell lysates 
with calf intestinal phosphatase (CIP) rescued cyclin G2 from degradation. To gain a deeper 
understanding and trying to find the protein kinase that phosphorylates cyclin G2, the protein’s 
primary sequence was interrogated using Group-Based Prediction System (GPS) software and 
epidermal growth factor receptor (EGFR) was obtained as one of the candidates. This finding is 
particularly interesting because EGFR activation has been shown to also upregulate calpain 
activity113,115. To look for potential kinases involved in cyclin G2 degradation, a kinase inhibitor 
library was used to selectively block the activity of EGFR as well as other protein kinases 
downstream of it to see the effects on the levels of cyclin G2 in human ovarian cancer cells. Our 
results showed that inhibition of EGFR protected cyclin G2 from degradation in these cells, 
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whether the cells were stimulated with EGF or not. Inhibition of EGFR also protected cyclin G2 
from degradation in cell lysates with added calpain. Therefore, activity of EGFR is involved in 
degradation of cyclin G2. Whether there is a direct interaction between EGFR and cyclin G2 where 
the latter becomes phosphorylated or if a downstream effector of EGFR is responsible for 
phosphorylating cyclin G2 remains to be explored. However, it is possible that EGFR is the kinase 
we are seeking, because even though signal transduction pathways are not at work once the cell is 
lysed, presence of Tyrphostin AG 1478, although not significantly, showed some protective effect 
against cyclin G2 degradation. Additionally, there is evidence that EGFR can be internalized and 
travel all the way to the nucleus where it drives the expression of genes such as cyclin D1125. The 
possibility of direct phosphorylation of cyclin G2 by EGFR remains to be investigated. 
 
EGF binding and subsequent activation of EGFR and downstream transduction pathways 
are important events in cancer development. EGFR-induced signals and gene expression patterns 
lead to an increase in cell proliferation, migration and invasion, adhesion, and angiogenesis while 
suppressing apoptotic pathways or those that negatively regulate cell cycle progression119,120,130. 
Another set of evidence which shows involvement of EGFR activity in cyclin G2 degradation 
comes from the results where cells were stimulated with EGF. We showed that treating a number 
of human ovarian cancer cells with EGF resulted in a decrease in the levels of cyclin G2. Using an 
inhibitor of the proteasome machinery which also inhibits calpain activity, MG-132, resulted in 
the attenuation of the effect of EGF on cyclin G2 stability. In this context, it is important to make 
room for the fact that mutations of EGFR in ovarian cancer126,127, which lead to an increased 
activity of the receptor and its downstream effectors and gene targets might mask the effect of 
added EGF; the receptors could already be fully active and additional EGF might not cause any 
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significant effect. It should be mentioned however that no attempts to characterize possible EGFR 
mutations have been made in our lab. It would be of interest to study the effects of EGF on cyclin 
G2 stability in healthy ovarian cells in addition to the investigations done in cancerous cells. 
 
One surprising finding was the apparent lack of activity of calpain-1 in degrading cyclin 
G2 as shown in Figure 9. While addition of calcium and calpain-1 showed a significant decrease 
in levels of cyclin G2 in Figure 7, such effect was absent in similar conditions. Although not 
confirmed yet, maybe the presence of DMSO, both as control as well as the vehicle for Tyrphostin 
AG 1478, might have contributed to attenuation of calpain-1 proteolytic activity. Alternatively, 
calpain-1 stock might have lost its activity. Revision of the protocols and studying the effect of 
DMSO on calpain-1 will shed more light on this curious result. 
 
At this point, it is worth mentioning a few overshadowing limitations that were experienced 
throughout the work presented here. First, we had no access to a reliable anti-cyclin G2 antibody 
to monitor the fate of endogenous cyclin G2. One consequence of this is that we were forced to 
work with tagged, exogenous cyclin G2 in order to detect and monitor its levels. In this regard, we 
have used both stable cells that constitutively express cyclin G2, which can pose a problem as 
mentioned earlier in Introduction (Table 2) with respect to the negative effects of cyclin G2 on cell 
cycle progression. Cell cycle which has deviated from its normal course will have other 
consequences in terms of the whole cellular molecular pathways, which can further us from a more 
physiologically-relevant conditions that cancer cells experience. A less intrusive way to study 
cyclin G2 was therefore to transiently express the FLAG-CCNG2 construct to reduce the myriad 
of effects which overexpression of this protein entails. For example, in the case of ES2 cells stably 
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expressing cyclin G2, after a few passages they stopped growing, and an approach centring 
transient transfection was chosen over using stable cells. Considering levels of cyclin G2 have 
been reported to be significantly lowered in various types of cancer, its overexpression is a logical 
method to study its function in these cells. However, any experiment that leads to introducing 
higher than normal amounts of cyclin G2 in the cells, should also make room for the inhibitory 
effects of abundant cyclin G2 on the cell cycle progression.  But as we know, proteins are not lone 
wolves in the cell, and any deviation from the normal levels of the proteins puts the cells in a very 
different situation. The other restriction, which has been explained in more detail under Future 
Directions was the lack of signal from expressing CCNG2 constructs with truncated or deleted 
PEST domain. Considering the pivotal role of PEST domain in regulating the degradation of cyclin 
G2, exciting discoveries are waiting to be made in the field to further uncover details of not only 
the role of PEST domain in degradation of cyclin G2, but to identify the important amino acid 
residues that are involved in this process. 
 
The fact that signal transduction pathways instigated by EGFR are a cascade of 
phosphorylation events, together with the findings in our lab indicating that treatment of cell 
lysates with CIP prevented cyclin G2 degradation, plus knowing that EGFR activation can also 
activate calpain, and that calpain-mediated protein degradation seems to depend on 
phosphorylation of the target protein, it is possible to propose a model for the mechanism of cyclin 
G2 degradation downstream of EGFR signalling cascades. Two major mechanisms are likely to 
be in play when it comes to degradation of cyclin G2 downstream of EGFR. FIRST, EGFR 
activation leads to phosphorylation of cyclin G2. Whether EGFR directly phosphorylates cyclin 
G2 or not as well as the spatial details of this process are excellent areas of investigation for the 
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future. In the same area, the residues phosphorylated on cyclin G2 are also waiting to be 
discovered. The phosphorylation event(s) then guide cyclin G2 degradation via two mechanisms, 
which leads us to the SECOND step. Cyclin G2 phosphorylation can act as a signal for 
ubiquitination and degradation by the UPP. As well, phosphorylation of cyclin G2 can result in 
interaction between cyclin G2 and calpain, which also leads to degradation of cyclin G2. Another 
major component of this model is the activation of calpain in response to EGFR activation. Figure 
12 represents a view of this proposed model. 
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For the figure legend please continue to next page. 
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Figure 12: A proposed model for EGFR and calpain-mediated degradation of cyclin G2. 
Activated EGFR directly or indirectly causes phosphorylation of cyclin G2. Phosphorylated 
cyclin G2 can be degraded by calpain protease activity, which can also be positively regulated 
through the action of ERK as a consequence of EGFR activation. Phosphorylated cyclin G2 is 
then ubiquitinated and sent to proteasome for degradation.  
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Chapter 5: Summary and Future Directions 
5.1: Summary 
  To summarize the findings, we have shown that cyclin G2 is an unstable protein, and is 
rapidly degraded in a number of human ovarian cancer cells. In addition to the previous findings 
by our lab that cyclin G2 is targeted by the proteasome for degradation, we have shown that cyclin 
G2 is also subject to degradation by calpain proteolytic activity. While investigating cyclin G2 
degradation in the context of signal transduction pathways we have revealed that EGFR signalling 
decreases cyclin G2 stability. In accordance with published data that EGFR signalling also 
positively regulates calpain activity, we studied the effect of EGFR inhibition on calpain-mediated 
degradation of cyclin G2, but did not find a significant effect of EGFR inhibition on the fate of 
cyclin G2 in the presence of calpain-1. Finally, we have provided evidence that stimulation of cells 
with EGF causes cyclin G2 degradation in human ovarian cancer cells, and that blocking the 
proteasome machinery attenuates the effect of EGF on cyclin G2 degradation.  
 
5.2: Future Directions 
  The crucial involvement of cyclin G2 PEST domain in its degradation has been 
demonstrated67, but unfortunately we did not succeed in getting expression from the constructs 
with various PEST domain deletions to collect information on how these deletions would affect 
cyclin G2 stability in these cells. Although these constructs were isolated using the same method 
as the ones that expressed well, multiple attempts at sequencing them failed, and so it was not even 
possible to determine if the lack of expression could be due to a nonsense mutation or not. 
Additionally, this problem could have been caused by mislabeled or old bacterial stock that were 
not maintained well. Very recent unpublished results from our lab have reported successful 
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expression of these constructs and have narrowed down the problem to the inefficiency of anti-V5 
antibody which was available at the time. Future studies that aim at investigating the stability of 
wild-type or modified versions of cyclin G2, should also monitor the stability of a number of other 
proteins, in order to provide a context in which stability of cyclin G2 can be better compared and 
contrasted to other proteins as well as in different cell lines, as stability of proteins can vary from 
one cell type to the next.  
 
  To study more aspects of cyclin G2 degradation and processes involved, fresh constructs 
with various modifications to the wild-type gene can be generated and used. More specifically, 
CCNG2 can be mutated on the residues known to facilitate direct interactions between cyclin G2 
and it known binding partners. Other mutations should focus on potential phosphorylation sites, 
which most likely serve as a starting signal for cyclin G2 degradation. Speaking of the involvement 
of kinases in degradation of cyclin G2, studying its phosphorylation state as a requirement for 
degradation can also be further studied through the use of constructs which harbour mutations of 
potential phosphorylation sites. 
 
  While chemical kinase inhibitors provide a relatively easy method to study the effects 
which inhibition of those kinases might have, some of them bear the disadvantage of low 
specificity for their target kinase; they could also inhibit other protein kinases. To have a tighter 
control over this process, siRNA could be used instead, to specifically silence only the protein 
kinase(s) under study. We are far from having full control over the processes employed by the 
cells to survive, and so the use of siRNA might prove to be an invaluable alternative or compliment 
to the use of chemical protein kinase inhibitors.  
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  Finally, performing experiments in healthy ovarian cell lines as well as in cell lines from 
different tissue origins, will provide us with a much broader view of the processes involved in 
cyclin G2 function and regulation, and will hopefully make comparisons and the lessons learned 
from those comparisons a more fruitful endeavour. These findings will be further enriched when 
we incorporate and consider the microenvironments and microbiota in which cancer cells form in 
and are surrounded by, respectively.  
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